The importance of a multidisciplinary approach to hepatocellular carcinoma

Abstract: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. The rising incidence, genetic heterogeneity, multiple etiologies, and concurrent chronic liver diseases make diagnosis, staging, and selection of treatment options challenging in patients with HCC. The best approach to optimize the management of HCC is one that utilizes a core multidisciplinary liver tumor board, consisting of hepatologists, pathologists, interventional radiologists, oncologists, hepatobiliary and transplant surgeons, nurses, and general practitioners. In most cases, HCC is diagnosed by abdominal imaging studies, preferably with a triphasic computed tomography scan of the abdomen or magnetic resonance imaging of the abdomen. Histopathological diagnosis using a guided liver biopsy may be needed in noncirrhotic patients or when radiological diagnostic criteria are not fulfilled in the setting of cirrhosis. The Barcelona Clinic Liver Cancer staging system facilitates a standardized therapeutic strategy based on the tumor burden, extent of metastasis, severity of hepatic decompensation, comorbid medical illnesses, functional status of patient, HCC-related symptoms, and preference of the patient. Treatment options include curative surgery (hepatic resection and liver transplantation) and palliative measures (radiofrequency ablation, transarterial chemoembolization, and chemotherapy with sorafenib). The role of the multidisciplinary team is crucial in promptly reconfirming the diagnosis, staging the HCC, and formulating an individualized treatment plan. In potential liver transplant candidates, timely liver transplant evaluation and coordinating bridging/downsizing treatment modalities, such as radiofrequency ablation and transarterial chemoembolization, can be time-consuming. In summary, a multidisciplinary team approach provides a timely, individualized treatment plan, which can vary from curative surgery in patients with early-stage HCC to palliative/hospice care in patients with metastatic HCC. In most tertiary care centers in the US, a multidisciplinary liver tumor board has become the standard of care and a key component of best practice protocol for patients with HCC.

Keywords: multidisciplinary team, MDT, hepatocellular carcinoma, HCC

Introduction

The importance of a multidisciplinary team in the management of cancer was highlighted in the National Health Services breast screening program.1,2 The goal of the multidisciplinary team was to improve the clinical outcomes for specific tumors starting with breast cancer,3 and more recently, hepatocellular carcinoma (HCC).4 HCC is the third leading cause of cancer-related deaths worldwide.5,6 The rising incidence of HCC is likely due to the increasing prevalence of chronic hepatitis C virus (HCV) infection.5,6 No single treatment strategy can be applied to all patients with HCC, necessitating a multidisciplinary approach to tailor a management plan based on tumor burden, extent...
of metastasis, severity of hepatic decompensation, comorbid medical conditions, functional status, cancer-related symptoms, and patient preference. The core members of multidisciplinary liver tumor board include liver transplant/hepatobiliary surgeons, hepatologists/gastroenterologists, oncologists, radiologists, interventional radiologists, pathologists, and primary care physicians. Furthermore, additional consultative services can be obtained based on the individual needs of the patients. The aim of this review is to highlight the significance of a multidisciplinary liver tumor board to optimize the management of HCC.

**Prompt diagnosis of HCC**

The clinical features of HCC may be subtle and/or nonspecific, and a delay in the diagnosis of HCC may lead to poor outcomes. In patients with cirrhosis, symptoms associated with HCC may overlap with end-stage liver disease; therefore, the importance of HCC screening and surveillance protocols must be discussed with patients with cirrhosis. To optimize patient care and improve clinical outcomes, patients with HCC can be managed by a multidisciplinary team, comprising of specialists with different roles, expertise, and functions. In patients with cirrhosis, hepatic decompensation can manifest as ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, bleeding from gastrointestinal varices, and hepatic encephalopathy. Patients who develop sudden-onset hepatic decompensation in the setting of cirrhosis should undergo an abdominal imaging study to rule out HCC. It is important to highlight that screening for HCC in patients with cirrhosis followed by surveillance every 6 months increases the likelihood of early-stage HCC diagnosis with potential for curative options. On the contrary, late diagnosis is associated with poor prognosis. A multidisciplinary liver tumor board provides a platform to promptly and optimally deliver any form of therapy following the diagnosis of HCC.

**Staging criteria for HCC**

The Barcelona Clinic Liver Cancer (BCLC) is a system that has been externally validated and is currently endorsed by the American Association for the Study of Liver Diseases, the European Society for Medical Oncology, and the European Association for the Study of the Liver. The stages within the BCLC system are linked to tumor burden, presence or absence of metastasis, extent of metastasis, hepatic functional reserve/severity of hepatic decompensation, physical/functional status, cancer-related symptoms, and patient preference. In addition, the BCLC system provides treatment guidance and predicts outcomes. Patients classified as having early-stage HCC (BCLC-A), defined as a single nodule or three nodules less than 3 cm in diameter, are eligible for potentially curative therapies such as hepatic resection or liver transplantation. Patients with intermediate-stage HCC (BCLC-B), those asymptomatic with multinodular tumors and without vascular invasion or extrahepatic spread, are eligible for locoregional therapy. Those with advanced-stage HCC (BCLC-C), who are symptomatic or have evidence of vascular invasion/extrahepatic spread, are eligible for sorafenib palliative therapy. Finally, patients with terminal-stage HCC (BCLC-D) have either severe cancer-related symptoms or severe hepatic decompensation (Child–Pugh class C) and may receive symptomatic palliative treatment only (Figure 1). Treatment options and management plan should be defined by a multidisciplinary liver tumor board (Figure 2) based on BCLC classification. Clinical trials and other experimental protocols available at the institution should be reviewed and offered to candidates who meet the inclusion criteria.

**Etiology of liver disease and pathogenesis of HCC**

Hepatitis B virus (HBV), HCV, alcoholic cirrhosis, aflatoxin b, nonalcoholic steatohepatitis, and hemochromatosis are some well-known causes of chronic liver disease. It is important to understand that a significant proportion of chronic liver disease can progress to cirrhosis (stage 4 hepatic fibrosis). Patients with advance stage 3 to 4 hepatic fibrosis are at risk for developing HCC. However, chronic HBV infection may result in HCC in the absence of cirrhosis. Therefore, it is important to start surveillance for HCC in patients with chronic HBV infection earlier on even in the absence of cirrhosis.

**Role of tumor biology of HCC**

The genetic and molecular heterogeneity of HCC complicates the understanding of this complex malignancy. Only a small proportion of HCC progresses rapidly without responding to bridging and/or downsizing treatments. Hence, the multidisciplinary liver tumor board should make an effort to identify cases of HCC that have the potential to grow rapidly and offer individualized therapy and evaluation to undergo treatment in the context of a clinical trial. Whole exome and genome sequencing has been implemented in order to determine the most common genetic mutations involved in HCC. Some previously reported gene mutations include TP53, CTNNB1, MLL4, MLL, ARID1a/2, and JAK1. Mutations
Multidisciplinary approach to hepatocellular carcinoma

Several studies have reported mutations in the switch/sucrose nonfermenting-related ATP-dependent nucleosome remodelers: ARID1A and ARID2.19 It is important for the oncologist and pathologist to be aware of the research and clinical advances on a molecular level and if studies are available for enrollment.

Improvement in treatment options for HCC

Liver transplantation was a controversial treatment option for HCC in the early years until Mazzaferro et al21 described 75% 4-year survival in a cohort of patients with HCC limited to a single tumor lesion ≤5 cm or up to three tumor lesions, none greater than 3 cm.22 This criteria, now known as the Milan criteria (Figure 3), has become the HCC listing criteria for liver transplantation. It has been shown that involvement of a multidisciplinary tumor board is associated with an improved 5-year survival in colorectal23 and esophageal cancers24 and with an improved 2-year survival in head and neck cancers.25,26

Locoregional treatment modalities play a critical role in the treatment of HCC. Figure 1 illustrates the Barcelona Clinic Liver Cancer staging system. Patients with early-stage disease are candidates for surgery, ablation, or percutaneous ethanol injection (PEI). Patients with intermediate-stage disease may be candidates for surgery, ablation, PEI, or transarterial chemoembolization (TACE). Patients with advanced-stage disease are candidates for TACE or sorafenib. Patients with terminal-stage disease are candidates for symptomatic treatment.

Figure 2 demonstrates the role of the multidisciplinary liver tumor board. The board consists of a gastroenterologist and hepatologist, a liver transplant program/hepatobiliary surgeon, an interventional and body radiologist, a medical oncologist and pathologist, a palliative care and hospice service, a primary care provider and pain management, a liver and cancer support group, and a patient with hepatocellular carcinoma. The board meets to discuss the best course of treatment for each patient, taking into account their individual needs and preferences.

The prevalence of mutations in p53 affect HCC recurrence, disease-free survival, and overall survival, which includes death from both HCC and the underlying liver disease.18 The prevalence of mutations in chromatin regulatory pathways further obscure the picture. Several studies have reported mutations in the switch/sucrose nonfermenting-related ATP-dependent nucleosome remodelers: ARID1A and ARID2.19 It is important for the oncologist and pathologist to be aware of the research and clinical advances on a molecular level and if studies are available for enrollment.

Figure 1 Barcelona Clinic Liver Cancer staging system.

Notes: Barcelona Clinic Liver Cancer stages: very early stage (0), early stage (A), intermediate stage (B), advanced stage (C), terminal stage (D), *Okuda: Okuda staging, N1 and M1 refer to TNM staging.

Abbreviations: HCC, hepatocellular carcinoma; PEI, percutaneous ethanol injection; PS, performance status; RCT, randomly controlled trial; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.

Figure 2 Multidisciplinary liver tumor board.
management of early or intermediate stage HCC via control of disease progression, tumor downstaging, and offering a bridge to liver transplantation. In advanced stages of the disease, the main aim is to control symptoms, prolong survival, and improve quality of life. Interventional radiology and surgery play a pivotal role in every stage of disease, with several options including direct ablation, portal vein embolization, transarterial embolization, transarterial chemoembolization, drug-eluting beads, and transarterial radioembolization. In each case, the rapid transfer of clinical knowledge among members of different specialties is essential to enhance the efficiency of treatment delivery and outcome. Long-term survival in patients with HCC diagnosed by screening improved significantly from 1998 to 2004 compared with the period from 1991 to 1997 due to the management of small HCC with liver transplantation and radiofrequency ablation. A multidisciplinary approach ensures that HCC is accurately staged and that treatment recommendations are evidence-based, patient-centered, and reached by consensus. Specialists with different roles, expertise, and functions are required to manage HCC due to its complex genetic, pathological, etiological, and oncological features. The contribution of each team member varies and depends on the institution-specific expertise and the stage of HCC at diagnosis. The BCLC classification forms the backbone for clinical decision making and facilitates an optimal and individualized management plan for patients with HCC. Rapid transfer of clinical information and seamless communication is required between members of the multidisciplinary liver tumor board, along with frequent (preferably on a weekly basis) joint conferences to discuss management plans. Treatment strategies for HCC employed in the setting of a multidisciplinary liver tumor board have demonstrated several advantages, such as doubling of patients referred for treatment, patients presenting with early-stage HCC, curative treatment proportions increasing from 6% to 19%, and palliative therapy increasing from 31% to 45%. Cirrhosis is evaluated using the Child–Turcotte–Pugh score/classification and the model for end-stage liver disease score. The complexity of these scoring and staging systems calls for interaction of various specialties at different stages of the disease. Gastroesophageal varices, ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, and hepatic encephalopathy often coincide with treatment of HCC, both during curative therapy and palliative care. Early recognition and treatment of each of these concurrent complications are vital for improving outcomes. Published literature have also backed the idea that an integrated multidisciplinary approach can help optimize the management of HCC patients. Published data have supported the concept of a multidisciplinary approach in improving patient experience. At our institution, we have had a multidisciplinary team for the management of HCC for the last 15 years, and the multidisciplinary approach to our patients with HCC is represented by Figure 2. A multidisciplinary liver tumor board optimizes the management of HCC patients by efficiently performing comprehensive consultations and developing their care plan. Our approach has been extremely convenient to patients and their families who at times travel from outreach clinics to our tertiary care center. In addition, the multidisciplinary approach helps physicians learn and review different protocols (experimental and standard of care) that are available. A multidisciplinary approach is the best practice
and the standard of care at major tertiary care centers in most developed and developing countries.

**Conclusion**

In patients with HCC, the rising incidence, genetic heterogeneity, multiple etiologies, and concurrent chronic liver diseases make diagnosis, staging, and selection of treatment options challenging. A multidisciplinary liver tumor board for HCC is beneficial in multiple ways. It can improve the management of patients through comprehensive and efficient consultations and through an offering of various options that are tailored on a case-by-case basis. In addition, a multidisciplinary approach offers physicians and other health care providers the opportunity to learn and review the variety of different protocols, experimental and/or approved, which are suitable for their patients. Furthermore, a multidisciplinary approach helps coordinate multiple clinic visits and scheduling for patients with advanced liver disease who are traveling long distances to their main tertiary care centers. In summary, a multidisciplinary approach for the management of HCC is the best practice and the standard of care at major tertiary care centers.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


